In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking ...
CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream. In ...
Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing ...
Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years. In his interview with ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...
At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing ...
Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains. In his interview with Pharmaceutical Commerce ahead of Asembia’s AXS26 Summit, Joel Wayment ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around ...
Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain ...
Raquel Vazquez discusses how data can be incorporated to make key decisions within the cold chain.
EPS for ~3-day lanes, polyurethane for higher performance, and vacuum insulation panels for maximum duration—still anchor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results